AN2 Therapeutics, Inc. (ANTX): Total Liabilities
$8.89M
As of 2025-12-31
$5.75M
As of 2026-06-30
+7.3%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.89M | -13.2% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $10.24M | -27.1% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $14.04M | +95.4% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $7.19M | +110.9% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $3.41M | n/a | 2023-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $8.89M | -13.2% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $28.52M | -23.6% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $5.93M | -46.4% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Rallybio Corp (RLYB) | 2025-12-31 | $4.30M | -33.3% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $5.02M | +291.6% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $56.36M | +0.9% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $31.58M | +23.2% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $33.06M | -3.2% |
Compare ANTX, LFVN, OKUR, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗